EU turns to private funding to boost quantum technology ambition
Quantum technology will make processing significantly faster than conventional computing, has the potential to impact every part of the economy and could be worth trillions of dollars within the next decade, according to McKinsey.
'We have to now focus more on private funding because we are very strong already in public funding,' Virkkunen told a news conference as she announced the EU Quantum Strategy.
The European Commission and EU countries have in the last five years provided more than 11 billion euros ($13 billion) in public funding to quantum technology.
'Only 5% of the global private investments on quantum are now coming to Europe. So we will especially work on the private funding part in the coming months,' Virkkunen said.
The EU Quantum Strategy also envisages EU countries pooling their expertise and resources in research, quantum infrastructures and the ecosystem of start-ups and scale-ups as well as focusing on dual use of the technology in security and defence.
Virkkunen said start-ups in particular should be helped.
'European quantum startups, they are vulnerable to being bought by foreign entities or moving to areas with better funding and this is why it is crucial to act now,' she said.
She said the Commission will propose legislation called a Quantum Act next year to build on the strategy.
($1 = 0.8501 euros)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
23 minutes ago
- Mint
Will the EU delay enforcing its AI Act?
Parts of EU's AI Act due to come into force on August 2 Publication of key guidance document has been delayed Some companies, politicians call for delay STOCKHOLM, July 3 (Reuters) - With less than a month to go before parts of the European Union's AI Act come into force, companies are calling for a pause in the provisions and getting support from some politicians. Groups representing big U.S. tech companies such as Google owner Alphabet and Facebook owner Meta, and European companies such as Mistral and ASML have urged the European Commission to delay the AI Act by years. WHAT IS THE AUGUST 2 DEADLINE? Under the landmark act that was passed a year earlier after intense debate between EU countries, its provisions would come into effect in a staggered manner over several years. Some important provisions, including rules for general purpose AI (GPAI) models, are due to apply on August 2. GPAI, which includes foundation models like those made by Google, Mistral and OpenAI, will be subject to transparency requirements such as drawing up technical documentation, complying with EU copyright law and providing detailed summaries about the content used for algorithm training. The companies will also need to test for bias, toxicity, and robustness before launching. AI models classed as posing a systemic risk and high-impact GPAI will have to conduct model evaluations, assess and mitigate risks, conduct adversarial testing, report to the European Commission on serious incidents and provide information on their energy efficiency. WHY DO COMPANIES WANT A PAUSE? For AI companies, the enforcement of the act means additional costs for compliance. And for ones that make AI models, the requirements are tougher. But companies are also unsure how to comply with the rules as there are no guidelines yet. The AI Code of Practice, a guidance document to help AI developers to comply with the act, missed its publication date of May 2. "To address the uncertainty this situation is creating, we urge the Commission to propose a two-year 'clock-stop' on the AI Act before key obligations enter into force," said an open letter published on Thursday by a group of 45 European companies. It also called for simplification of the new rules. Another concern is that the act may stifle innovation, particularly in Europe where companies have smaller compliance teams than their U.S. counterparts. The European Commission has not yet commented on whether it will postpone the enforcement of the new rules in August. However, EU tech chief Henna Virkkunen promised on Wednesday to publish the AI Code of Practice before next month. Some political leaders, such as Swedish Prime Minister Ulf Kristersson, have also called the AI rules "confusing" and asked the EU to pause the act. "A bold 'stop-the-clock' intervention is urgently needed to give AI developers and deployers legal certainty, as long as necessary standards remain unavailable or delayed," tech lobbying group CCIA Europe said.
&w=3840&q=100)
Business Standard
31 minutes ago
- Business Standard
Biocon Biologics secures EU approval for Vevzuo and Evfraxy biosimilars
Biocon arm Biocon Biologics has received marketing authorisation from the European Commission for Vevzuo and Evfraxy – biosimilars of Denosumab used to treat bone diseases. The marketing authorisation follows a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on 25 April 2025, Biocon added. Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour (GCT) of bone. Meanwhile, Evfraxy is authorised for the treatment of osteoporosis in men with prostate cancer at increased risk of fractures or treatment of bone loss associated with long-term systemic glucocorticoid therapy in adults. 'The approval of Vevzuo and Evfraxy in Europe underscores our strong scientific expertise and commitment to expanding patient access to essential medicines, including new therapeutic areas such as bone health. In the past 18 months, we have secured regulatory approvals for three biosimilars in Europe and two in the UK. These Denosumab biosimilars mark another significant milestone in our rapid expansion, and support for regional healthcare systems,' said Shreehas Tambe, CEO and managing director, BBL. Clinical data demonstrated that both Denosumab biosimilars exhibit comparable quality, safety, and efficacy to the reference product, the company claimed. Analysts said that the space is already crowded, and the opportunity for Biocon could be around $20 million. Nuvama Institutional Equities said that Sandoz, Samsung, and Celltrion have already received approval, with several other filers including Stada/Alvotech, Teva, Fresenius, and Shanghai Henlius and Organon awaiting entry. The European market is estimated at $1.5 billion. Assuming 75 per cent price erosion and a 5 per cent market share, the opportunity for Biocon could be $20 million, Nuvama said.
Time of India
an hour ago
- Time of India
Diogo Jota killed in car accident: What was Liverpool star's net worth, endorsements and market value?
Liverpool star Diogo Jota has been killed in a car accident in Spain, police said Thursday. He was 28, a father of three young children and had married his long-term partner, Rute Cardoso, less than two weeks ago. Jota and his brother, 26-year-old André, who was also killed, were travelling in a car that came off a road in the province of Zamora. The cause of the accident, which happened at about midnight on Wednesday, is not clear, but according to police reports the driver lost control after one of the car's rear tyres was punctured. The car burst into flames and firefighters had to extinguish a blaze in the surrounding countryside caused by the accident. The Liverpool Football Club said they are devastated by the tragic passing of Diogo Jota."The club have been informed the 28-year-old has passed away following a road traffic accident in Spain along with his brother, Andre. Liverpool FC will be making no further comment at this time and request the privacy of Diogo and Andre's family, friends, teammates and club staff is respected as they try to come to terms with an unimaginable loss. We will continue to provide them with our full support," it said. ALSO READ: Diogo Jota dies in car crash: Lamborghini tyre burst, flames, and two bodies, here's how the accident happened Diogo Jota net worth According to a report in TOI, Diogo Jota's net worth was estimated to fall between $12 million and $20 million, built through lucrative contracts with elite clubs like Liverpool, Atlético Madrid, and Wolverhampton Wanderers, alongside various endorsements and sponsorship deals. Live Events At Liverpool, his reported weekly wage was around £140,000 ($187,000), amounting to an annual base salary of approximately £7.3 million ($9 million), excluding performance-related bonuses. His contract with the club extended through 2027, underscoring his value as a vital member of the squad. Jota's endorsements and market value Diogo Jota's journey through professional football has been marked not just by impressive performances but also by a steady rise in earnings. He began his career at Paços de Ferreira before securing a move to Atlético Madrid. However, it was in the Premier League with Wolverhampton Wanderers that Jota truly made his mark, paving the way for a high-profile transfer to Liverpool in 2020. At Liverpool, Jota quickly became a key player, which led to a lucrative five-year contract extension in 2022. His weekly wages rose to approximately £140,000, pushing his annual salary past £7 million. Over the course of his career, Jota's total income—including salaries, signing bonuses, and performance-based incentives—is estimated to have surpassed £40 million (roughly $50 million). In addition to his club earnings, Jota has significantly boosted his income through brand endorsements and a growing presence on social media. His rising profile in European football made him a popular choice for sponsorships, bringing in hundreds of thousands of dollars more each year. According to Transfermarkt, Jota's market value peaked at around €60 million ($65 million), highlighting his status as one of the top forwards in the game. Diogo Jota career and profile Diogo Jota was born on December 4, 1996 and was only linked with a move to Liverpool 24 hours prior to him signing a five-year contract with the English champions, according to Liverpool. Having begun his career in his homeland with Pacos de Ferreira, Jota's rapid progress following a debut in 2014 had prompted Atletico to swoop for his services in 2016 – though he never actually appeared for the Spanish club. Instead, he spent 2016-17 on loan at FC Porto, scoring eight times in the Primeira Liga and gaining Champions League experience, including a goal against Leicester City, Liverpool said. He netted 17 goals in the Championship as Wolves were promoted in 2017/18 and added 16 goals to his name in the Premier League before he signed for Liverpool. ALSO READ: Meta boss Mark Zuckerberg 'asked to leave' Oval Office meeting? Know what was Trump discussing with officials By 2020, as Liverpool looked to build on their recent Premier League and Champions League successes, Jürgen Klopp saw Diogo Jota as an ideal addition to his squad. Jota made an immediate impact, hitting double figures in goals within just 21 appearances—despite a knee injury in December sidelining him for nearly three months during his debut season. He stepped up even further in the 2021–22 campaign, scoring 21 goals across all competitions and playing a crucial role in Liverpool's FA Cup and Carabao Cup triumphs, while the team came agonizingly close to winning both the Premier League and Champions League. He returned to action as a seventieth minute substitute against Everton on 13 February. He initially failed to score in eleven games but a double in the 6-1 rout of Leeds at Elland Road on 17 April set him on his way. By the end of the campaign he had added give more league goals, the most memorable being an injury time winner against Tottenham at Anfield after the Reds had let a 3-0 lead slip. Jota's 2023/24 season was also disrupted by injury, with knee and muscle problems limiting him to 21 appearances.
